Twelve is a carbon transformation company focused on converting CO2 into essential products through innovative electrochemical technology. Their flagship products include E-Jet® SAF and CO2Made® materials, which are designed to eliminate industrial emissions and provide sustainable alternatives to fossil fuels. By leveraging their proprietary Opus™ system, Twelve aims to revolutionize the production of hydrocarbons, making them from air instead of oil. The company is positioned at the forefront of the sustainable fuels market, partnering with major brands like Alaska Airlines and Mercedes-Benz to drive the transition to a fossil-free future. With a strong commitment to industrial innovation, Twelve is well-positioned to capture significant market share in the growing demand for sustainable materials and fuels.
Modern Meadow is a pioneer in sustainable materials, creating innovative biomaterials like BIO-VERA® that replace petrochemical and animal-derived inputs. Their technology platform allows seamless integration into existing manufacturing processes, enabling industries such as fashion, footwear, and automotive to produce high-quality, sustainable products. With over 250,000 handbags and jackets produced and 11 global partners, Modern Meadow is positioned as a leader in bioinnovation, driving sustainability and performance in material production.
Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-moving and immune-mediated diseases. Our FDA cleared INTELLISEP test is pioneering a new way of quickly and accurately analyzing white blood cells to stratify a patient’s risk of sepsis by performing a biomechanical evaluation of white blood cells collected from a standard blood draw in under 10 minutes. Cytovale’s first market application will be for sepsis, one of the fastest-moving, most lethal conditions in the world. Sepsis, a dysregulated immune response to infection, is often difficult to quickly and accurately diagnose. Sepsis is the No. 1 cause of death in hospitals, taking the lives of 270,000 people every year in the U.S. – more than opioid overdoses, prostate cancer, and breast cancer combined. Mortality from sepsis increases as much as eight percent with every hour of delayed treatment, and as much as 80 percent of sepsis deaths could be prevented with rapid diagnostics.
Zymochem is breakthrough science for a fossil-free future. We accelerate the transition to a real-zero economy by developing bio-based materials for everyday products. Are you interested in learning more about how our high-performance biomaterials are replacing petrochemical ingredients? We are seeking candidates who are motivated by science and innovation and have a passion to push the boundaries of materials performance. We are collaborative, multidisciplinary, and relentlessly committed to creating a chemicals and materials industry in tune with the 21st century. If this sounds exciting, we want to hear from you! Please visit: www.zymochem.com/careers Zymochem. Creating the fossil-free future.
Parallel Bio is pioneering the use of immune organoids and AI to revolutionize drug discovery, focusing on immunotherapies that leverage the human immune system. By creating in-vitro models that accurately replicate human immune responses, the company aims to eliminate the inefficiencies and ethical concerns associated with traditional animal testing. Their platform allows for rapid, cost-effective development of therapies that are designed to work in humans from the outset, significantly reducing the time and financial burden typically associated with drug development. With a strong emphasis on scalability and population diversity, Parallel Bio is positioned to transform the landscape of immunotherapy and address previously untreatable diseases, collaborating with major pharmaceutical and biotech companies to bring innovative solutions to market.
Life exists in motion. Cellchorus® applies visual AI to evaluate thousands of microscopy experiments in parallel to improve the development and delivery of novel therapies for biopharmaceutical and research customers. The company's time-lapse imaging microscopy in nanowell grids (TIMING™) platform provides high-throughput evaluation of how individual cells move, behave, interact, and perform.
